Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Metrics to compare | IPHA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPHAPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.4x | −2.4x | −0.7x | |
PEG Ratio | −0.07 | −0.12 | 0.00 | |
Price / Book | 4.0x | 1.4x | 2.6x | |
Price / LTM Sales | 3.4x | 4.4x | 3.2x | |
Upside (Analyst Target) | - | 202.5% | 45.9% | |
Fair Value Upside | Unlock | 3.8% | 7.6% | Unlock |